Israel Englander’s Lucid Diagnostics LUCD Stock Holding History

Israel Englander’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,320	Closed	-$13K	–	6176
2026 Q1	$13K	Sell	11,320 -142,598	-93%	-$181K	﹤0.01%	5524
2025 Q4	$168K	Buy	+153,918	New	+$172K	﹤0.01%	5518
2025 Q2	–	Sell	-204,047	Closed	-$304K	–	6142
2025 Q1	$304K	Buy	+204,047	New	+$245K	﹤0.01%	5096
2023 Q1	–	Sell	-17,814	Closed	-$24K	–	6643
2022 Q4	$24K	Sell	17,814 -6,602	-27%	-$11.9K	﹤0.01%	6002
2022 Q3	$37K	Buy	24,416 +151	+0.6%	+$376	﹤0.01%	6275
2022 Q2	$55K	Buy	+24,265	New	+$53.9K	﹤0.01%	6164
2022 Q1	–	Sell	-65,315	Closed	-$351K	–	7235
2021 Q4	$351K	Buy	+65,315	New	+$530K	﹤0.01%	5382

Other funds holding LUCD

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Israel Englander's LUCD Position: Q2 2026 in Review

Israel Englander sold out of Lucid Diagnostics (LUCD) in Q2 2026, closing a stake of 11,320 shares — an estimated $13K sold.

Israel Englander first reported a position in LUCD in Q4 2021 and held it in 7 quarters. The position peaked at $351K in Q4 2021. 114 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

Israel Englander reported no remaining Lucid Diagnostics position as of Q2 2026 after selling out during the quarter.
Israel Englander sold 11,320 Lucid Diagnostics shares in Q2 2026, an estimated $13K.
Israel Englander first reported a position in Lucid Diagnostics in Q4 2021 and held it in 7 quarters.
Israel Englander's Lucid Diagnostics position peaked at $351K in Q4 2021.
114 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.